Aldosterone synthase inhibition: a novel bullet to fight cardiovascular-kidney-metabolic syndrome.

SUMMARY: Extensive research has examined the effects of growth hormone (GH) replacement therapy for patients with hypopituitarism and GH deficiency. Positive outcomes, encompassing both conventional clinical markers and improvements in quality of life (QoL), have led to its incorporation in current clinical practice guidelines. Herein, we present how routine use of the patient-reported outcome measures information system (PROMIS) as an intuitive tool portraying patient-reported outcome measures (PROMs) can help guide and follow-up therapeutic decisions and bridge the gap between clinical parameters and patient experiences. This approach is illustrated by a patient with panhypopituitarism and HIV with low antiretroviral medication adherence. Following the initiation of GH replacement therapy, PROMIS assessments documented QoL improvements that enabled full resumption of antiretroviral medication, accompanied by resolution of previously experienced adverse effects.

LEARNING POINTS: GH replacement can be an important component of hormone replacement therapy in individuals with hypopituitarism and suicidal ideations. Incorporating PROMs into endocrinological care can help guide therapy decisions in patients with hypopituitarism. Clinical signs attributed to side effects of antiretroviral therapy may overlap with those of GH deficiency, and GH replacement therapy can potentially increase medication adherence.